Laurion Capital Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Laurion Capital Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-11,504	Closed	-$887K	–	495
2022 Q1	$887K	Buy	+11,504	New	+$963K	0.01%	257
2021 Q3	–	Sell	-379,356	Closed	-$31.7M	–	693
2021 Q2	$31.7M	Buy	379,356 +3,484	+0.9%	+$276K	0.18%	114
2021 Q1	$28.4M	Buy	375,872 +363,899	+3,039%	+$29.7M	0.15%	132
2020 Q4	$1.05M	Buy	+11,973	New	+$949K	0.01%	405
2019 Q4	–	Sell	-40,066	Closed	-$2.7M	–	912
2019 Q3	$2.7M	Buy	+40,066	New	+$3.09M	0.02%	444
2018 Q4	–	Sell	-266	Closed	-$26K	–	1119
2018 Q3	$26K	Buy	+266	New	+$26.6K	﹤0.01%	1127

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Laurion Capital Management's BMRN Position: Q2 2022 in Review

Laurion Capital Management sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 11,504 shares — an estimated $887K sold.

Laurion Capital Management first reported a position in BMRN in Q3 2018 and held it in 6 quarters. The position peaked at $31.7M in Q2 2021. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Laurion Capital Management reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Laurion Capital Management sold 11,504 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $887K.
Laurion Capital Management first reported a position in BioMarin Pharmaceuticals in Q3 2018 and held it in 6 quarters.
Laurion Capital Management's BioMarin Pharmaceuticals position peaked at $31.7M in Q2 2021.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Laurion Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.